NCT04500418View on ClinicalTrials.gov

Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

July 27, 2021

Study Completion Date

July 27, 2021

Conditions
Covid19
Interventions
DRUG

Cenicriviroc (CVC)

Treatment with Cenicriviroc tablets of 150mg. (450g/300g on day 1 and 300mg/d on days 2-28).

DRUG

Placebo

Optically identical pills without CVC.

Trial Locations (1)

10117

Medical Department of Hepatology and Gastroenterology, Charité University Medicine, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin

Sponsors

Collaborators (1)

Allergan
All Listed Sponsors
collaborator

Allergan

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER